- This topic is empty.
-
Posts
-
-
This page contains summary of CNBC program “Mad Money w/ Jim Cramer” which was on air on Thursday, February 8, 2024. It also contains links to CNBC sites which contain video clips and transcripts.
(1) Jim Cramer looks outside the Magnificent Seven, names other companies with shares that are popping (https://www.cnbc.com/2024/02/08/jim-cramer-names-stocks-that-are-popping-outside-the-magnificent-7.html)
- CNBC’s Jim Cramer told investors there’s money to be made in several companies besides the megacap tech stocks.
- He pointed to companies that could yield higher gains than low-risk investments like CDs.
(2) Executive Interview: CEO explains why GE Healthcare’s research and development is focused on AI (https://www.cnbc.com/2024/02/08/ceo-explains-why-ge-healthcare-is-so-focused-on-ai.html)
- GE Healthcare CEO Peter Arduini told CNBC’s Jim Cramer about developing AI products, including technology to make patient data more cohesive.
- AI can also also enhance imaging, and Arduini said customers are willing to pay up for advanced technology.
Ticker: GEHC
(3) [No Video Clip for non-Club Member] If you don’t own Arm yet, wait for the stock to pull back when the lockup expires, says Jim Cramer (https://www.cnbc.com/video/2024/02/08/if-you-dont-own-arm-yet-wait-for-the-stock-to-pull-back-when-the-lockup-expires-says-jim-cramer.html)
‘Mad Money’ host Jim Cramer digs into the recent jump in Arm stock and how to play it from here.
Ticker: ARM
(4) [No Video Clip for non-Club Member] Executive Interview: Vertex Pharma CEO Kewalramani sits down with Jim Cramer (https://www.cnbc.com/video/2024/02/08/vertex-pharma-ceo-kewalramani-sits-down-with-jim-cramer.html)
Vertex Pharma President and CEO Dr. Reshma Kewalramani joins ‘Mad Money’ host Jim Cramer to talk sickle cell gene therapy, cystic fibrosis treatments and more.
Ticker: VRTX
(5) Cramer’s Lightning Round: AbbVie is ‘a very good company’ (https://www.cnbc.com/2024/02/08/cramers-lightning-round-abbvie-is-a-very-good-company.html)
- Oxford Lane Capital: “We don’t know if they’re any good at credit, and we don’t know what they own. I like the concept, and in that sense, I think I would look at Blackstone, because they really know how to do it.”
- MercadoLibre: “I was an original investor in Mercado Libre, and I have never once abandoned it. Those people are incredibly smart.”
- Freeport-McMoRan: “I think it could go up a couple of points, once the Chinese start manipulating their market higher, but that’s all you’re going to get from them. We have to go higher quality.”
- AbbVie: ”…It’s a very good company.”
Ticker: OXLC, MELI, FCX, ABBV
(6) [No Video Clip for non-Club Member] Someone needs to teach these large language models how to be better actors, says Jim Cramer (https://www.cnbc.com/video/2024/02/08/someone-needs-to-teach-these-large-language-models-how-to-be-better-actors-says-jim-cramer.html)
‘Mad Money’ host Jim Cramer digs into Google launching Gemini chatbot.
Ticker: GOOGL
Other Stocks Discussed (calls with audience): CrowdStrike (CRWD) [54 weeks high today, wait to buy], Box (BOX) [go for more proprietary, more semiconductor]
Ref: Links to other sites that relate to episode of February 8, 2024
- Podcast at Spotify (Sound from Spotify）
- Internet Archive（Video & Texts per minute）
****************************
Previous episode Next Episode
-
- The topic ‘Mad Money: Key points from February 8, 2024 (Thursday) Episode’ is closed to new replies.